Stavudine (Synonyms: 司他夫定; d4T)

目錄號(hào): HY-B0116 純度: 99.87%: FAQs
Data Sheet SDS COA 產(chǎn)品使用指南技術(shù)支持

Stavudine (d4T) 是一種口服活性核苷逆轉(zhuǎn)錄酶抑制劑 (NRTI)。Stavudine 具有抗 HIV-1 和 HIV-2 的活性。Stavudine 還抑制線粒體 DNA (mtDNA) 的復(fù)制。Stavudine 降低 NLRP3 炎癥小體激活，調(diào)節(jié)淀粉樣 β 自噬。Stavudine 誘導(dǎo)細(xì)胞凋亡。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)

Stavudine Chemical Structure

CAS No. : 3056-17-5

1. 客戶無(wú)需承擔(dān)相應(yīng)的運(yùn)輸費(fèi)用。

2. 同一機(jī)構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機(jī)構(gòu)（單位）一年內(nèi)

可免費(fèi)申領(lǐng)三個(gè)不同產(chǎn)品的試用裝。

3. 試用裝只面向終端客戶。

規(guī)格	價(jià)格	是否有貨
10 mM * 1 mL in DMSO	￥495	In-stock
100 mg	￥450	In-stock
500 mg	￥950	In-stock
1 g		詢價(jià)
5 g		詢價(jià)

or 大包裝詢價(jià)

* Please select Quantity before adding items.

Customer Review

Other Forms of Stavudine:

Stavudine (Standard) In-stock
Stavudine-13C,d3 詢價(jià)
Stavudine-d₄ 詢價(jià)
Stavudine sodium 詢價(jià)

MCE 顧客使用本產(chǎn)品發(fā)表的 3 篇科研文獻(xiàn)

•Int J Antimicrob Agents. 2019 Dec;54(6):814-819. [Abstract]
•Toxicology. 2020 Jun;439:152443. [Abstract]
•Biotechnol Bioeng. 2021 Sep 3. [Abstract]

Stavudine 相關(guān)產(chǎn)品

•相關(guān)化合物庫(kù):

•同靶點(diǎn)產(chǎn)品:

•同靶點(diǎn)蛋白產(chǎn)品:

查看 HIV 亞型特異性產(chǎn)品:

查看所有亞型

HIV HIV-1 HIV-2

查看 NOD-like Receptor (NLR) 亞型特異性產(chǎn)品:

查看所有亞型

NLRP3 NLRP1 NOD1 NOD2

生物活性
純度 & 產(chǎn)品資料
參考文獻(xiàn)

生物活性

Stavudine (d4T) is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Stavudine has activity against HIV-1 and HIV-2. Stavudine also inhibits the replication of mitochondrial DNA (mtDNA). Stavudine reduces NLRP3 inflammasome activation and modulates Amyloid-β autophagy. Stavudine induces apoptosis^[1]^[2]^[3]^[4].

IC₅₀ & Target

HIV-1

HIV-2

NLRP3

細(xì)胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
Caco-2	IC₅₀	> 250 μM Compound: 2, d4T	Cytostatic activity against human Caco2 cells assessed as growth inhibition after 3 days by particle counting analysis Cytostatic activity against human Caco2 cells assessed as growth inhibition after 3 days by particle counting analysis	[PMID: 24177359]
CCRF-CEM	IC₅₀	> 10 μM Compound: 1 (d4T)	Compound was tested for anti-HIV activity in TK-deficient CEM cells by microculture tetrazolium assay Compound was tested for anti-HIV activity in TK-deficient CEM cells by microculture tetrazolium assay	[PMID: 9873688]
CCRF-CEM	CC₅₀	> 100 μM Compound: Stavudine	Cytotoxic concentration of compound required to reduce the viability of mock infected CEM cells by 50% Cytotoxic concentration of compound required to reduce the viability of mock infected CEM cells by 50%	[PMID: 14980640]
CCRF-CEM	IC₅₀	> 250 μM Compound: 2, d4T	Cytostatic activity against thymidine kinase-deficient human CEM cells assessed as growth inhibition after 3 days by particle counting analysis Cytostatic activity against thymidine kinase-deficient human CEM cells assessed as growth inhibition after 3 days by particle counting analysis	[PMID: 24177359]
CCRF-CEM	CC₅₀	> 50 μM Compound: 1a; d4T	Cytotoxicity in human CEM/0 cells assessed as reduction in cell viability incubated for 4 to 5 days Cytotoxicity in human CEM/0 cells assessed as reduction in cell viability incubated for 4 to 5 days	[PMID: 32515595]
CCRF-CEM	IC₅₀	≥ 250 μM Compound: 2, d4T	Cytostatic activity against human CEM cells assessed as growth inhibition after 3 days by particle counting analysis Cytostatic activity against human CEM cells assessed as growth inhibition after 3 days by particle counting analysis	[PMID: 24177359]
CCRF-CEM	EC₅₀	0.16 μM Compound: 1 (d4T)	Compound was evaluated for the inhibition of HIV replication using HIV-1 infected CEM cells. Compound was evaluated for the inhibition of HIV replication using HIV-1 infected CEM cells.	10.1016/0960-894X(96)00195-3
CCRF-CEM	EC₅₀	0.27 μM Compound: 1 (d4T)	Compound was evaluated for the inhibition of HIV replication using HIV-2 infected CEM cells. Compound was evaluated for the inhibition of HIV replication using HIV-2 infected CEM cells.	10.1016/0960-894X(96)00195-3
CCRF-CEM	EC₅₀	0.39 μM Compound: 2, d4T	Antiviral activity against HIV1 3B infected in human CEM cells assessed as virus-induced giant cell formation after 4 days by microscopic analysis Antiviral activity against HIV1 3B infected in human CEM cells assessed as virus-induced giant cell formation after 4 days by microscopic analysis	[PMID: 24177359]
CCRF-CEM	EC₅₀	0.56 μM Compound: 1, (d4T)	Antiviral activity against HIV1 in wild type human CEM cells assessed as virus-induced cytopathic effect after 4 to 5 days by microscopy Antiviral activity against HIV1 in wild type human CEM cells assessed as virus-induced cytopathic effect after 4 to 5 days by microscopy	[PMID: 19438207]
CCRF-CEM	EC₅₀	0.58 μM Compound: 2, d4T	Antiviral activity against HIV2 ROD infected in human CEM cells assessed as virus-induced giant cell formation after 4 days by microscopic analysis Antiviral activity against HIV2 ROD infected in human CEM cells assessed as virus-induced giant cell formation after 4 days by microscopic analysis	[PMID: 24177359]
CCRF-CEM	IC₅₀	0.6 μM Compound: 1 (d4T)	Compound was tested for anti-HIV activity in TK-deficient CEM cells by p24 production assay Compound was tested for anti-HIV activity in TK-deficient CEM cells by p24 production assay	[PMID: 9873688]
CCRF-CEM	EC₅₀	0.651 μM Compound: d4T	Concentration required to protect CEM cells against cytopathicity of HIV-1 by 50% Concentration required to protect CEM cells against cytopathicity of HIV-1 by 50%	[PMID: 10714505]
CCRF-CEM	EC₅₀	0.77 μM Compound: d4T	Concentration required to protect CEM cells against cytopathicity of HIV-2 by 50% Concentration required to protect CEM cells against cytopathicity of HIV-2 by 50%	[PMID: 10714505]
CCRF-CEM	EC₅₀	0.78 μM Compound: d4T, stavudine	Antiviral activity against HIV-1 infected in wild type CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days Antiviral activity against HIV-1 infected in wild type CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days	[PMID: 22827702]
CCRF-CEM	EC₅₀	0.79 μM Compound: 1, (d4T)	Antiviral activity against HIV2 in wild type human CEM cells assessed as virus-induced cytopathic effect after 4 to 5 days by microscopy Antiviral activity against HIV2 in wild type human CEM cells assessed as virus-induced cytopathic effect after 4 to 5 days by microscopy	[PMID: 19438207]
CCRF-CEM	EC₅₀	1.3 μM Compound: d4T, stavudine	Antiviral activity against HIV-2 infected in wild type CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days Antiviral activity against HIV-2 infected in wild type CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days	[PMID: 22827702]
CCRF-CEM	EC₅₀	150 μM Compound: d4T, stavudine	Antiviral activity against HIV-2 infected in thymidine kinase deficient CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days Antiviral activity against HIV-2 infected in thymidine kinase deficient CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days	[PMID: 22827702]
CCRF-CEM	CC₅₀	174 μM Compound: d4T	Compound was evaluated for the cytotoxicity against CEM cell proliferation by 50% Compound was evaluated for the cytotoxicity against CEM cell proliferation by 50%	[PMID: 10714505]
CCRF-CEM	CC₅₀	174 μM Compound: 1	Cytostatic concentration required to inhibit CEM/0 cells proliferation by 50% Cytostatic concentration required to inhibit CEM/0 cells proliferation by 50%	[PMID: 10514282]
CCRF-CEM	IC₅₀	2.4 μM Compound: 1 (d4T)	Compound was tested for anti-HIV activity in TK-deficient CEM cells by inhibition of reverse transcriptase activity Compound was tested for anti-HIV activity in TK-deficient CEM cells by inhibition of reverse transcriptase activity	[PMID: 9873688]
CCRF-CEM	EC₅₀	25 μM Compound: 1 (d4T)	Compound was evaluated for the inhibition of HIV replication using HIV-2 infected CEM-TK- cells. Compound was evaluated for the inhibition of HIV replication using HIV-2 infected CEM-TK- cells.	10.1016/0960-894X(96)00195-3
CCRF-CEM	EC₅₀	29 μM Compound: 1, (d4T)	Antiviral activity against HIV2 in thymidine kinase deficient human CEM cells assessed as virus-induced cytopathic effect after 4 to 5 days by microscopy Antiviral activity against HIV2 in thymidine kinase deficient human CEM cells assessed as virus-induced cytopathic effect after 4 to 5 days by microscopy	[PMID: 19438207]
CCRF-CEM	EC₅₀	31.05 μM Compound: 1; d4T	Antiviral activity against HIV2 ROD infected in thymidine kinase-deficient human CEM cells assessed as inhibition of virus-induced giant cell formation measured after 4 to 5 days by microscopic analysis Antiviral activity against HIV2 ROD infected in thymidine kinase-deficient human CEM cells assessed as inhibition of virus-induced giant cell formation measured after 4 to 5 days by microscopic analysis	[PMID: 32421343]
CCRF-CEM	EC₅₀	33 μM Compound: d4T	Concentration required to protect CEM/TK- cells against cytopathicity of HIV-2 by 50% Concentration required to protect CEM/TK- cells against cytopathicity of HIV-2 by 50%	[PMID: 10714505]
CCRF-CEM	CC₅₀	79 μM Compound: d4T	Cytotoxicity against human CEM/0 cells assessed as reduction in cell proliferation incubated for 4 to 5 days Cytotoxicity against human CEM/0 cells assessed as reduction in cell proliferation incubated for 4 to 5 days	[PMID: 26125628]
CCRF-CEM	CC₅₀	93 μM Compound: 1 (D4T)	Cytostatic concentration required to inhibit Human T-Lymphocyte (CEM) cells proliferation caused by HIV-1 (IIIB) Cytostatic concentration required to inhibit Human T-Lymphocyte (CEM) cells proliferation caused by HIV-1 (IIIB)	[PMID: 12852759]
CEM-c113	EC₅₀	0.08 μM Compound: D4T	Effective concentration that reduces HIV-induced cytopathic effect by 50% was determined by MTT assay. Effective concentration that reduces HIV-induced cytopathic effect by 50% was determined by MTT assay.	[PMID: 8385224]
COLO 320	IC₅₀	159 μM Compound: 2, d4T	Cytostatic activity against human COLO320 cells assessed as growth inhibition after 3 days by particle counting analysis Cytostatic activity against human COLO320 cells assessed as growth inhibition after 3 days by particle counting analysis	[PMID: 24177359]
H9	EC₅₀	0.06 μM Compound: D4T, NSC-163661	Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique	[PMID: 11430019]
H9	EC₅₀	0.06 μM Compound: D4T, NSC-163661	Antiviral activity against HIV1 RF in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique Antiviral activity against HIV1 RF in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique	[PMID: 11430019]
HEK-293T	CC₅₀	> 100 μM Compound: d4T	Cytotoxicity against human 293T cells assessed as inhibition of cell proliferation by tetrazolium dye method Cytotoxicity against human 293T cells assessed as inhibition of cell proliferation by tetrazolium dye method	[PMID: 17470654]
HeLa	EC₅₀	> 200 μM Compound: d4T, Stavudine	Cytotoxicity against human HeLa P4/R5 cells by MTS assay Cytotoxicity against human HeLa P4/R5 cells by MTS assay	[PMID: 21382714]
HeLa	IC₅₀	> 250 μM Compound: 2, d4T	Cytostatic activity against thymidine kinase-deficient human HeLa cells assessed as growth inhibition after 3 days by particle counting analysis Cytostatic activity against thymidine kinase-deficient human HeLa cells assessed as growth inhibition after 3 days by particle counting analysis	[PMID: 24177359]
HeLa	IC₅₀	> 250 μM Compound: 2, d4T	Cytostatic activity against human HeLa cells assessed as growth inhibition after 3 days by particle counting analysis Cytostatic activity against human HeLa cells assessed as growth inhibition after 3 days by particle counting analysis	[PMID: 24177359]
L1210	IC₅₀	≥ 250 μM Compound: 2, d4T	Cytostatic activity against thymidine kinase-deficient mouse L1210 cells assessed as growth inhibition after 2 days by particle counting analysis Cytostatic activity against thymidine kinase-deficient mouse L1210 cells assessed as growth inhibition after 2 days by particle counting analysis	[PMID: 24177359]
L1210	IC₅₀	8.9 μM Compound: 2, d4T	Cytostatic activity against mouse L1210 cells assessed as growth inhibition after 2 days by particle counting analysis Cytostatic activity against mouse L1210 cells assessed as growth inhibition after 2 days by particle counting analysis	[PMID: 24177359]
MT2	IC₅₀	> 100 μM Compound: 1, d4T	Cytotoxicity against human MT2 cells after 5 days by MTT assay Cytotoxicity against human MT2 cells after 5 days by MTT assay	[PMID: 23380374]
MT2	CC₅₀	> 100 μM Compound: d4T	Cytotoxicity against human MT2 cells after 5 days by MTT assay Cytotoxicity against human MT2 cells after 5 days by MTT assay	[PMID: 20605472]
MT2	CC₅₀	> 100 μM Compound: d4T	Cytotoxicity against human MT2 cells by MTT assay Cytotoxicity against human MT2 cells by MTT assay	[PMID: 20304641]
MT2	CC₅₀	> 100 μM Compound: d4T	Cytotoxicity against human MT2 cells infected with HIV1 harboring reverse transcriptase Y181C mutation by MTT assay Cytotoxicity against human MT2 cells infected with HIV1 harboring reverse transcriptase Y181C mutation by MTT assay	[PMID: 20304641]
MT2	CC₅₀	> 100 μM Compound: d4T	Cytotoxicity against human MT2 cells infected with HIV1 harboring reverse transcriptase K103N/Y181C mutation by MTT assay Cytotoxicity against human MT2 cells infected with HIV1 harboring reverse transcriptase K103N/Y181C mutation by MTT assay	[PMID: 20304641]
MT2	CC₅₀	> 100 μM Compound: d4t	Cytotoxicity against human MT2 cells by MTT assay Cytotoxicity against human MT2 cells by MTT assay	[PMID: 17918923]
MT2	CC₅₀	> 100 μM Compound: d4T	Cytotoxicity against human MT2 cells by MTT assay Cytotoxicity against human MT2 cells by MTT assay	[PMID: 16298131]
MT2	EC₅₀	0.5 μM Compound: d4T	Antiviral activity against HIV1 reverse transcriptase K103N/Y181C double mutant infected in human MT2 cells assessed as inhibition of viral replication by MTT assay Antiviral activity against HIV1 reverse transcriptase K103N/Y181C double mutant infected in human MT2 cells assessed as inhibition of viral replication by MTT assay	[PMID: 20304641]
MT2	EC₅₀	0.7 μM Compound: d4T	Antiviral activity against HIV1 reverse transcriptase Y181C mutant infected in human MT2 cells assessed as inhibition of viral replication by MTT assay Antiviral activity against HIV1 reverse transcriptase Y181C mutant infected in human MT2 cells assessed as inhibition of viral replication by MTT assay	[PMID: 20304641]
MT2	EC₅₀	1.4 μM Compound: d4T	Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of virus replication by MTT assay Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of virus replication by MTT assay	[PMID: 20304641]
MT2	EC₅₀	1.6 μM Compound: d4t	Antiviral activity against HIV1 3B in human MT2 cells by MTT assay Antiviral activity against HIV1 3B in human MT2 cells by MTT assay	[PMID: 17918923]
MT2	CC₅₀	100 μM Compound: Stavudine	Cytotoxic concentration required to reduce the viability of mock-infected MT-2 cells by 50% Cytotoxic concentration required to reduce the viability of mock-infected MT-2 cells by 50%	[PMID: 14552777]
MT2	EC₅₀	2 μM Compound: d4T	Antiviral activity against HIV1 3B in MT2 cells assessed as inhibition of viral-mediated T-cell death by MTT method Antiviral activity against HIV1 3B in MT2 cells assessed as inhibition of viral-mediated T-cell death by MTT method	[PMID: 17317163]
MT2	CC₅₀	2.2 μM Compound: d4T	Cytotoxicity against human MT2 cells after 5 days by MTT assay Cytotoxicity against human MT2 cells after 5 days by MTT assay	[PMID: 24900627]
MT2	EC₅₀	2.2 μM Compound: 1, d4T	Antiviral activity against HIV-1 infected un MT2 cells assessed as virus-induced cytopathicity after 5 days by MTT assay Antiviral activity against HIV-1 infected un MT2 cells assessed as virus-induced cytopathicity after 5 days by MTT assay	[PMID: 23380374]
MT2	EC₅₀	2.3 μM Compound: d4T	Antiviral activity against HIV1 3B infected in human MT-2 cells assessed as inhibition of viral-mediated cell death after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT-2 cells assessed as inhibition of viral-mediated cell death after 5 days by MTT assay	[PMID: 20605472]
MT2	EC₅₀	3 μM Compound: d4T	Antiviral activity against HIV1 3B in MT2 cells by MTT assay Antiviral activity against HIV1 3B in MT2 cells by MTT assay	[PMID: 16298131]
MT2	EC₅₀	3.6 μM Compound: d4T	Antiviral activity against HIV1 3B infected in human MT2 cells after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT2 cells after 5 days by MTT assay	[PMID: 24900627]
MT2	EC₅₀	4.8 μM Compound: 5	Inhibition of virus-induced cytopathic effect in wild type HIV 3a infected MT2 cells after 5 days Inhibition of virus-induced cytopathic effect in wild type HIV 3a infected MT2 cells after 5 days	[PMID: 17562366]
MT4	EC₅₀	0.51 μM Compound: Stavudine	Antiviral activity against HIV1 3B in MT4 cells by MTT assay Antiviral activity against HIV1 3B in MT4 cells by MTT assay	[PMID: 17181169]
MT4	IC₅₀	1.2 μM Compound: 1	Concentration required for the inhibition of HIV replication by 50% in MT-4 cells Concentration required for the inhibition of HIV replication by 50% in MT-4 cells	10.1016/S0960-894X(00)80147-X
SUP-T1	EC₅₀	136.1 μM Compound: d4T, Stavudine	Antiviral activity against Human immunodeficiency virus 1 3B infected in human SupT1 cells by cell-associated transmission assay Antiviral activity against Human immunodeficiency virus 1 3B infected in human SupT1 cells by cell-associated transmission assay	[PMID: 21382714]
WI-38	CC₅₀	> 100 μM Compound: Stavudine	Cytotoxicity against human WI38 cells by neutral red assay Cytotoxicity against human WI38 cells by neutral red assay	[PMID: 18285481]
WI-38	EC₅₀	> 100 μM Compound: Stavudine	Antimicrobial activity against BK polyomavirus ATCC VR837 infected in human WI38 cells assessed as reduction in viral titer after 7 days by PCR analysis Antimicrobial activity against BK polyomavirus ATCC VR837 infected in human WI38 cells assessed as reduction in viral titer after 7 days by PCR analysis	[PMID: 18285481]

體外研究
(In Vitro)

Stavudine (d4T) (50 μM) significantly reduces the expression of the NLRP3 inflammasome gene, IL-18 production and Aβ 42-stimulated cellular production of IL-1β in THP-1 derived macrophages^[3].
? Stavudine (d4T) (50 μM) inhibits the assembly of the NLRP3 inflammasome complex and down-regulates the phagocytosis of Aβ 42 by macrophages^[3].
? Stavudine (d4T) (10 μM, 7 or 14 days) significantly induced CEM cells apoptosis, especially after 14 days, and increases hydrogen peroxide levels^[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

體內(nèi)研究
(In Vivo)

Stavudine (d4T) (500 mg/kg, daily liquid, 2 weeks) can rapidly induce fat depletion and mild liver damage at high dose in male RjOrl Swiss mice^[5].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male RjOrl Swiss mice weighing 0.028-0.03 kg^[1]
Dosage:	500 mg/kg
Administration:	Daily liquid; 2 weeks
Result:	Reduced fat weight gain by 58%, 5.7 g in the control group and 4.9 g in the d4T treated group. Significantly elevated plasma ALT and LDH levels. Reduced plasma acetoacetic acid and beta-hydroxybutyric acid levels. Reduced liver and muscle mtDNA levels at high dose concentration of 500 mg/kg.

Clinical Trial

分子量

224.21

Formula

C₁₀H₁₂N₂O₄

CAS 號(hào)

3056-17-5

性狀

固體

顏色

White to light yellow

中文名稱

司他夫定

運(yùn)輸條件

Room temperature in continental US; may vary elsewhere.

儲(chǔ)存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

溶解性數(shù)據(jù)

細(xì)胞實(shí)驗(yàn)：

DMSO 中的溶解度 : 125 mg/mL (557.51 mM; 超聲助溶; 吸濕的 DMSO 對(duì)產(chǎn)品的溶解度有顯著影響，請(qǐng)使用新開(kāi)封的 DMSO)

H₂O 中的溶解度 : 16.67 mg/mL (74.35 mM; 超聲助溶)

配制儲(chǔ)備液

濃度溶劑體積質(zhì)量	1 mg	5 mg	10 mg

1 mM	4.4601 mL	22.3005 mL	44.6010 mL
5 mM	0.8920 mL	4.4601 mL	8.9202 mL
10 mM	0.4460 mL	2.2301 mL	4.4601 mL

查看完整儲(chǔ)備液配制表

* 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；一旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
儲(chǔ)備液的保存方式和期限：-80°C, 1 year; -20°C, 6 months。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?年內(nèi)使用， -20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)月內(nèi)使用。

* 備注：如您選擇水作為儲(chǔ)備液，請(qǐng)稀釋至工作液后，再用 0.22 μm 的濾膜過(guò)濾除菌后使用。

摩爾計(jì)算器
稀釋計(jì)算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

濃度 _(start)

體積 _(start)

濃度 _(final)

體積 _(final)

動(dòng)物實(shí)驗(yàn)：

請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥方式選擇適當(dāng)?shù)娜芙夥桨浮?

以下溶解方案都請(qǐng)先按照 In Vitro 方式配制澄清的儲(chǔ)備液，再依次添加助溶劑：
——為保證實(shí)驗(yàn)結(jié)果的可靠性，澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的工作液，建議您現(xiàn)用現(xiàn)配，當(dāng)天使用；
以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過(guò)加熱和/或超聲的方式助溶

方案一

請(qǐng)依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (11.15 mM); 澄清溶液

此方案可獲得 ≥ 2.5 mg/mL（飽和度未知）的澄清溶液。
以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水定容至 1 mL。
生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。
方案二

請(qǐng)依序添加每種溶劑： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (11.15 mM); 澄清溶液

此方案可獲得 ≥ 2.5 mg/mL（飽和度未知）的澄清溶液。
以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液中，混合均勻。
2 g SBE-β-CD（磺丁基醚 β-環(huán)糊精）粉末定容于 10 mL 的生理鹽水中，完全溶解至澄清透明。
方案三

請(qǐng)依序添加每種溶劑： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (11.15 mM); 澄清溶液

此方案可獲得 ≥ 2.5 mg/mL（飽和度未知）的澄清溶液，此方案實(shí)驗(yàn)周期在半個(gè)月以上的動(dòng)物實(shí)驗(yàn)酌情使用。
以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 900 μL玉米油中，混合均勻。

以下溶解方案，請(qǐng)直接配制工作液。建議現(xiàn)用現(xiàn)配，在短期內(nèi)盡快用完。以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過(guò)加熱和/或超聲的方式助溶。

方案一

請(qǐng)依序添加每種溶劑： PBS
Solubility: 120 mg/mL (535.21 mM); 澄清溶液; 超聲助溶

動(dòng)物溶解方案計(jì)算器

請(qǐng)輸入動(dòng)物實(shí)驗(yàn)的基本信息：

給藥劑量

mg/kg

動(dòng)物的平均體重

每只動(dòng)物的給藥體積

μL

動(dòng)物數(shù)量

只

由于實(shí)驗(yàn)過(guò)程有損耗，建議您多配一只動(dòng)物的量

計(jì)算結(jié)果

工作液所需濃度 : mg/mL

該產(chǎn)品水溶性佳，請(qǐng)具體參考實(shí)測(cè) 水 / PBS / Saline 中的溶解度數(shù)據(jù)。

您所需的儲(chǔ)備液濃度超過(guò)該產(chǎn)品的實(shí)測(cè)溶解度，如有需要，請(qǐng)與 MCE 中國(guó)技術(shù)支持聯(lián)系。

純度 & 產(chǎn)品資料

純度: 99.87%

選擇批次：

Data Sheet (634 KB) SDS (418 KB)

COA (197 KB) LCMS (94 KB)

產(chǎn)品使用指南 (1538 KB)

參考文獻(xiàn)

[1]. Moyle GJ, et al. The role of stavudine in the management of adults with HIV infection. Antivir Ther. 1997;2(4):207-218. [Content Brief]

[2]. Riddler SA, et al. Antiretroviral activity of stavudine (2',3'-didehydro-3'-deoxythymidine, D4T). Antiviral Res. 1995;27(3):189-203. [Content Brief]

[3]. La Rosa F, et al. Stavudine Reduces NLRP3 Inflammasome Activation and Modulates Amyloid-β Autophagy. J Alzheimers Dis. 2019;72(2):401-412. [Content Brief]

[4]. Ferraresi R, et al. Protective effect of acetyl-L-carnitine against oxidative stress induced by antiretroviral drugs. FEBS Lett. 2006;580(28-29):6612-6616. [Content Brief]

[5]. Anissa Igoudjil, et al. High doses of stavudine induce fat wasting and mild liver damage without impairing mitochondrial respiration in mice. Antivir Ther. 2007;12(3):389-400. [Content Brief]

Stavudine 相關(guān)分類

Infection

完整儲(chǔ)備液配制表

可選溶劑	濃度溶劑體積質(zhì)量	1 mg	5 mg	10 mg	25 mg

H₂O / DMSO	1 mM	4.4601 mL	22.3005 mL	44.6010 mL	111.5026 mL
	5 mM	0.8920 mL	4.4601 mL	8.9202 mL	22.3005 mL
	10 mM	0.4460 mL	2.2301 mL	4.4601 mL	11.1503 mL
	15 mM	0.2973 mL	1.4867 mL	2.9734 mL	7.4335 mL
	20 mM	0.2230 mL	1.1150 mL	2.2301 mL	5.5751 mL
	25 mM	0.1784 mL	0.8920 mL	1.7840 mL	4.4601 mL
	30 mM	0.1487 mL	0.7434 mL	1.4867 mL	3.7168 mL
	40 mM	0.1115 mL	0.5575 mL	1.1150 mL	2.7876 mL
	50 mM	0.0892 mL	0.4460 mL	0.8920 mL	2.2301 mL
	60 mM	0.0743 mL	0.3717 mL	0.7434 mL	1.8584 mL
DMSO	80 mM	0.0558 mL	0.2788 mL	0.5575 mL	1.3938 mL
DMSO	100 mM	0.0446 mL	0.2230 mL	0.4460 mL	1.1150 mL

* 備注：如您選擇水作為儲(chǔ)備液，請(qǐng)稀釋至工作液后，再用 0.22 μm 的濾膜過(guò)濾除菌后使用。

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

產(chǎn)品名稱：			* 需求量：
* 客戶姓名：			* Email：
* 電話：			* 公司或機(jī)構(gòu)名稱：
留言給我們：

產(chǎn)品名稱：			* Lot #：
* 客戶姓名：			* Email：
電話：			* 部門：
* 公司或機(jī)構(gòu)名稱：
留言給我們：

MedChemExpress (MCE) 只為有資質(zhì)的科研機(jī)構(gòu)、醫(yī)藥企業(yè)基于科學(xué)研究或藥證申報(bào)的用途提供醫(yī)藥研發(fā)服務(wù)，不為任何個(gè)人或者非科研性質(zhì)的、非用于藥證申報(bào)使用等其他用途提供服務(wù)。	站點(diǎn)地圖隱私聲明
滬ICP備15051369號(hào)-4 上海工商滬公網(wǎng)安備31011502019417 滬(浦)應(yīng)急管危經(jīng)許[2021]201709(QFYS) 營(yíng)業(yè)執(zhí)照（三證合一）
Copyright ? 2013-2025 MedChemExpress. All Rights Reserved.

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Stavudine (Synonyms: 司他夫定; d4T)

Customer Review

Other Forms of Stavudine:

MCE 顧客使用本產(chǎn)品發(fā)表的 3 篇科研文獻(xiàn)

Stavudine 相關(guān)產(chǎn)品

•相關(guān)化合物庫(kù):

•同靶點(diǎn)產(chǎn)品:

•同靶點(diǎn)蛋白產(chǎn)品:

查看 HIV 亞型特異性產(chǎn)品:

查看 NOD-like Receptor (NLR) 亞型特異性產(chǎn)品:

生物活性

純度 & 產(chǎn)品資料

參考文獻(xiàn)

摩爾計(jì)算器

稀釋計(jì)算器

Stavudine 相關(guān)分類

完整儲(chǔ)備液配制表

Keywords:

您最近查看的產(chǎn)品:

熱門區(qū)域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
郵箱 *

Sorry, but the email address you supplied was invalid.

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Stavudine (Synonyms: 司他夫定; d4T)

Customer Review

Other Forms of Stavudine:

Stavudine 相關(guān)抗體

MCE 顧客使用本產(chǎn)品發(fā)表的 3 篇科研文獻(xiàn)

Stavudine 相關(guān)產(chǎn)品

•相關(guān)化合物庫(kù):

•同靶點(diǎn)產(chǎn)品:

•同靶點(diǎn)蛋白產(chǎn)品:

查看 HIV 亞型特異性產(chǎn)品:

查看 NOD-like Receptor (NLR) 亞型特異性產(chǎn)品:

生物活性

純度 & 產(chǎn)品資料

參考文獻(xiàn)

Stavudine 相關(guān)抗體:

摩爾計(jì)算器

稀釋計(jì)算器

Stavudine 相關(guān)分類

完整儲(chǔ)備液配制表

Keywords:

您最近查看的產(chǎn)品:

Request for HNMR Report

Request for HNMR Report

熱門區(qū)域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z